Christopher Nixon Cox - Feb 1, 2024 Form 3 Insider Report for Alto Neuroscience, Inc. (ANRO)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	ANRO	Series B Preferred Stock							Feb 1, 2024	Common Stock	589K		By Lightswitch Capital Fund I, L.P.	F1, F2
holding	ANRO	Series C Preferred Stock							Feb 1, 2024	Common Stock	127K		By Lightswitch Capital Fund I, L.P.	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Each share of Series B Preferred Stock is convertible at any time, at the holder's election, and will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.1226069 for 1 basis into the number of shares of Common Stock shown in column 3 and has no expiration date.
F2	The shares are directly held by Lightswitch Capital Fund I, L.P. ("Lightswitch Capital"), of which Lightswitch Capital GP, LLC ("Lightswitch GP") is the sole general partner and exercises voting and investment power over these shares. The Reporting Person is the Chief Executive Officer of Lightswitch GP and disclaims beneficial ownership of these securities, except to the extent of his proportionate pecuniary interest therein.
F3	Each share of Series C Preferred Stock is convertible at any time, at the holder's election, and will automatically convert into shares of Common Stock immediately prior to the closing of the Issuer's initial public offering on a 2.2241 for 1 basis into the number of shares of Common Stock shown in column 3 and has no expiration date.